A5056530735- Estrogen and related hormone effects
- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- Cancer Genomics and Diagnostics
- Histone Deacetylase Inhibitors Research
- Epigenetics and DNA Methylation
- Cancer Risks and Factors
- HER2/EGFR in Cancer Research
- Pharmacogenetics and Drug Metabolism
- Cancer survivorship and care
- Cancer Immunotherapy and Biomarkers
- BRCA gene mutations in cancer
- Menopause: Health Impacts and Treatments
- Protein Degradation and Inhibitors
- Click Chemistry and Applications
- Cancer, Lipids, and Metabolism
- Medical Imaging Techniques and Applications
- PARP inhibition in cancer therapy
- Breast Lesions and Carcinomas
- Genetic factors in colorectal cancer
- Inflammatory mediators and NSAID effects
- DNA Repair Mechanisms
- Cancer Cells and Metastasis
- Cancer-related molecular mechanisms research
Johns Hopkins University
2016-2025
Sidney Kimmel Comprehensive Cancer Center
2016-2025
Weill Cornell Medicine
2024-2025
Cornell University
2005-2025
Cornell College
2025
University of Baltimore
2011-2024
Johns Hopkins Medicine
2015-2024
Johns Hopkins Hospital
2011-2023
Brunswick (United States)
2020-2023
Society of Surgical Oncology
2020-2023
Background: The efficacy of tamoxifen therapy for the treatment breast cancer varies widely among individuals. Plasma concentrations active metabolite endoxifen are associated with cytochrome P450 (CYP) 2D6 genotype. We examined effects concomitant use selective serotonin reuptake inhibitor antidepressants, which CYP2D6 enzyme inhibitors commonly prescribed to treat hot flashes in women who take tamoxifen, and genotypes genes that encode tamoxifen-metabolizing enzymes on plasma its...
Tamoxifen, a selective estrogen receptor modulator (SERM), is converted to 4-hydroxy-tamoxifen and other active metabolites by cytochrome P450 (CYP) enzymes. Selective serotonin reuptake inhibitors (SSRIs), which are often prescribed alleviate tamoxifen-associated hot flashes, can inhibit CYPs. In prospective clinical trial, we tested the effects of coadministration tamoxifen SSRI paroxetine, an inhibitor CYP2D6, on metabolism.Tamoxifen its were measured in plasma 12 women known CYP2D6...
To update the ASCO clinical practice guideline on adjuvant endocrine therapy basis of emerging data optimal duration treatment, particularly tamoxifen.ASCO convened Update Committee and conducted a systematic review randomized trials from January 2009 to June 2013 analyzed three historical trials. Guideline recommendations were based Committee's evidence. Outcomes interest included survival, disease recurrence, adverse events.This reflects tamoxifen treatment. There have been five studies...
Neoadjuvant (primary systemic) treatment is the standard for locally advanced breast cancer and a option primary operable disease. Because of new treatments understandings cancer, however, recommendations published in 2003 regarding neoadjuvant disease required updating. Therefore, second international panel representatives number clinical research groups was convened September 2004 to update these recommendations. As part this effort, data date were reviewed critically indications newly defined.
Adjuvant therapy with an aromatase inhibitor improves outcomes, as compared tamoxifen, in postmenopausal women hormone-receptor-positive breast cancer.In two phase 3 trials, we randomly assigned premenopausal early cancer to the exemestane plus ovarian suppression or tamoxifen for a period of 5 years. Suppression estrogen production was achieved use gonadotropin-releasing-hormone agonist triptorelin, oophorectomy, irradiation. The primary analysis combined data from 4690 patients...
Patients with hormone receptor-negative breast cancer generally do not benefit from endocrine-targeted therapies. However, a subset androgen receptor (AR) expression is predicted to respond antiandrogen This phase II study explored bicalutamide in AR-positive, estrogen (ER), and progesterone (PgR)-negative metastatic cancer.Tumors patients ER/PgR-negative advanced were tested centrally for AR [immunohistochemistry (IHC) > 10% nuclear staining considered positive]. If either the primary or...
In the Suppression of Ovarian Function Trial (SOFT) and Tamoxifen Exemestane (TEXT), 5-year rates recurrence breast cancer were significantly lower among premenopausal women who received aromatase inhibitor exemestane plus ovarian suppression than those tamoxifen suppression. The addition to did not result in with alone. Here, we report updated results from two trials.
Context Standard therapy for hot flashes has been hormone replacement with estradiol or progestational agents, but recent data suggest that antidepressants inhibiting serotonin reuptake may also be effective. Objective To evaluate a selective inhibitor (paroxetine controlled release [CR]) in treating the vasomotor symptoms displayed by general cross-section of menopausal women. Design and Setting Randomized, double-blind, placebo-controlled, parallel group study conducted across 17 US sites,...
Epigenetic therapy is emerging as a potential for solid tumors. To investigate its mechanism of action, we performed integrative expression and methylation analysis 63 cancer cell lines (breast, colorectal, ovarian) after treatment with the DNA methyltransferase inhibitor 5-azacitidine (AZA). Gene Set Enrichment Analysis demonstrated significant enrichment immunomodulatory pathways in all three cancers (14.4-31.3%) including interferon signaling, antigen processing presentation,...
The identification of patients with metastatic triple-negative breast cancer (mTNBC) who are expected to benefit from platinum-based chemotherapy is interest. We conducted a single-arm phase II clinical trial single-agent platinum for mTNBC biomarker correlates.Patients received first- or second-line cisplatin (75 mg/m(2)) carboplatin (area under the concentration-time curve 6) by physician's choice once every 3 weeks. Coprimary end points were objective response rate (RR) and prediction...
Detecting circulating plasma tumor DNA (ptDNA) in patients with early-stage cancer has the potential to change how oncologists recommend systemic therapies for solid tumors after surgery. Droplet digital polymerase chain reaction (ddPCR) is a novel sensitive and specific platform mutation detection.In this prospective study, primary breast matched pre- postsurgery blood samples were collected from (n = 29). Tumors 30) analyzed by Sanger sequencing common PIK3CA mutations, these then...
Aromatase inhibitors (AIs) are effective for treatment of hormone receptor-positive breast cancer, but adherence and persistence with therapy poor. Predictors discontinuation not clearly defined. It is unknown whether patients intolerable toxicity from one AI able to tolerate another.Women early-stage cancer initiating were enrolled onto a multicenter, prospective, open-label randomized trial exemestane versus letrozole. Patients completed symptom questionnaires at baseline serially during...
We sought to evaluate the feasibility of detecting PIK3CA mutations in circulating tumor DNA (ctDNA) from plasma patients with metastatic breast cancer using a novel technique called BEAMing.
Purpose This focused update addresses the use of MammaPrint (Agendia, Irvine, CA) to guide decisions on adjuvant systemic therapy. Methods ASCO uses a signals approach facilitate guideline updates. For this update, publication phase III randomized MINDACT (Microarray in Node-Negative and 1 3 Positive Lymph Node Disease May Avoid Chemotherapy) study evaluate assay 6,693 women with early-stage breast cancer provided signal. An expert panel reviewed results along other published literature...
BackgroundAdjuvant tamoxifen therapy substantially decreases the risk of recurrence and mortality in women with hormone (estrogen and/or progesterone) receptor–positive breast cancer. Previous studies have suggested that metabolic conversion to endoxifen by cytochrome P450 2D6 (CYP2D6) is required for patient benefit from therapy.
To update recommendations on appropriate use of breast cancer biomarker assay results to guide adjuvant endocrine and chemotherapy decisions in early-stage cancer.An updated literature search identified randomized clinical trials prospective-retrospective studies published from January 2016 October 2021. Outcomes interest included overall survival disease-free or recurrence-free survival. Expert Panel members used informal consensus develop evidence-based recommendations.The 24 informing the...
In patients with hormone-dependent postmenopausal breast cancer, standard adjuvant therapy involves 5 years of the nonsteroidal aromatase inhibitors anastrozole and letrozole. The steroidal inhibitor exemestane is partially non-cross-resistant a mild androgen could prove superior to regarding efficacy toxicity, specifically less bone loss.We designed an open-label, randomized, phase III trial versus two-sided test superiority detect 2.4% improvement in 5-year event-free survival (EFS)....
This focused update addresses the use of Oncotype DX in guiding decisions on adjuvant systemic therapy.ASCO uses a signals approach to facilitate guideline updating. For this update, publication Trial Assigning Individualized Options for Treatment (TAILORx) evaluating noninferiority endocrine therapy alone versus chemoendocrine invasive disease-free survival women with scores provided signal. An expert panel reviewed results TAILORx along other published literature assay assess evidence...
JCO